Optical method for the detection of cervical neoplasias using fluorescence spectroscopy

• US 5,612,540 A
• Filed: 03/31/1995
• Issued: 03/18/1997
• Est. Priority Date: 03/31/1995
• Status: Expired due to Term

• Current Assignee: Board of Regents of the University of Texas System (University of Texas System)
• Original Assignee: Board of Regents of the University of Texas System (University of Texas System)
• Inventors: Yazdi, Youseph, Staerkel, Gregg, Mitchell, Michele F., Richards-Kortum, Rebecca
• Primary Examiner(s): Fields, Carolyn E.
• Assistant Examiner(s): Glick, Edward J.
• Application Number:
  US08/412,325
• Time in Patent Office: 718 Days
• Field of Search: 250/459.1, 250/461.2
• US Class Current: 250/461.2
• CPC Class Codes: A61B 5/0071 by measuring fluorescence emission
• CPC Class Codes: A61B 5/0075 by spectroscopy, i.e. measuring spectra, e.g. Raman spectroscopy, infrared absorption spectroscopy A61B5/0071 takes precedence
• CPC Class Codes: A61B 5/0084 for introduction into the body, e.g. by catheters A61B5/1459 takes precedence
• CPC Class Codes: A61B 5/4331 of the cervix A61B5/435 takes precedence
• CPC Class Codes: A61B 5/7264 Classification of physiological signals or data, e.g. using neural networks, statistical classifiers, expert systems or fuzzy systems neural networks per se G06N3/00; expert systems per se G06N5/00
• CPC Class Codes: G01N 2021/6417 Spectrofluorimetric devices
• CPC Class Codes: G01N 2021/6423 Spectral mapping, video display
• CPC Class Codes: G01N 21/6456 Spatial resolved fluorescence measurements; Imaging
• CPC Class Codes: G01N 21/6486 Measuring fluorescence of biological material, e.g. DNA, RNA, cells G01N21/6428 takes precedence
• CPC Class Codes: G01N 2201/129 Using chemometrical methods

Abstract

A method for detecting tissue abnormality, particularly precancerous cervical tissue, through fluorescence spectroscopy is disclosed. In vitro fluorescence measurements over a variety of different fluorescence spectra are used to screen tissue samples. Using a principal component analysis (PCA), it is possible to discriminate between normal and dysplastic tissues with relatively low false-positive and false-negative results.

Claims

1. A method of detecting tissue abnormality in a tissue sample in vitro comprising:

(i) providing a tissue sample;

(ii) sequentially illuminating said tissue sample in vitro with a set of at least two electromagnetic radiation wavelengths selected to cause said tissue sample to produce a set of fluorescence intensity spectra indicative of tissue abnormality;

(iii) detecting said set of fluorescence intensity spectra emitted from said tissue sample as a result of illumination with each of said wavelengths; and

(iv) calculating from said set of fluorescence intensity spectra, a probability that said tissue sample is normal or abnormal.

2. The method of claim 1, wherein said calculating step comprises, conducting principal component analysis of said fluorescent spectra relative to a set of preprocessed spectra obtained from tissue samples of known pathology.

3. The method of claim 2, wherein said principal component analysis does not include the highest and lowest order principal components.

4. The method of claim 3, wherein said principal component analysis comprises a Fisher'"'"'s determinant analysis.

5. The method of claim 1, wherein said calculating step comprises, normalizing said spectra relative to a maximum intensity within said spectra.

6. The method of claim 5, wherein said calculating step further comprises, mean-scaling said spectra as a function of a mean intensity of spectra.

7. The method of claim 1, wherein said providing step comprises obtaining said tissue sample by biopsy.

8. The method of claim 7, wherein said providing step further comprises ethanol fixation of said tissue sample.

9. The method of claim 8, wherein said providing step even further comprises generating a monolayer cell touch preparation or a pellet.

10. The method of claim 1, wherein said set of at least two electromagnetic wavelengths are 250 nm, 550 nm and all wavelengths between 250 nm and 550 nm at 10 nm intervals.

11. The method of claim 1, wherein said detecting step comprises, detecting an intensity of fluorescence at 250 nm, 700 nm and all wavelengths between 250 nm and 700 nm at 10 nm intervals.

12. The method of claim 1, wherein said illuminating comprises, illuminating said sample substantially normal to a surface of said sample, and wherein said detecting step comprises, detecting said spectra at an angle of approximately 20°

from normal.

13. The method of claim 1, wherein at least 10 sequential electromagnetic radiation wavelengths are used in said illuminating step to produce a set of at least 10 different fluorescence intensity spectra in said detecting step, each spectra comprising fluorescence intensity at at least 11 wavelengths.

14. The method of claim 13, wherein at least 30 sequential electromagnetic radiation wavelengths are used in said illuminating step to produce a set of at least 30 different fluorescence intensity spectra in said detecting step, each spectra comprising fluorescence intensity at at least 31 wavelengths.

15. The method of claim 14, wherein at least 50 sequential electromagnetic radiation wavelengths are used in said illuminating step to produce a set of at least 50 different fluorescence intensity spectra in said detecting step, each said spectra comprising fluorescence intensity at at least 51 wavelengths.